Rayont Inc.
RAYT
Other OTC0.03
USD
- -
- -
CIK
0001539778
ISIN
US75508M1009
CUSIP
75508M100
Return %
Stock
S&P500
1Y
- -
18.02
3Y
-98.51
64.11
5Y
-41.92
70.77
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Marshini Aliya Moodley
- Full Time Employees
- 58
- Sector
- Technology
- Industry
- Software - Application
- Address
- 26 Marine Parade Southport QLD Australia 4215
- IPO Date
- Dec 5, 2012
- CIK
- 0001539778
- Website
- rayont.com
- Similar Companies
- Business
- Rayont Inc (RAYT) is a clinical-stage life sciences and healthcare company focused on alternative medicine, personalized natural healthcare, and biotechnology solutions including next-generation photodynamic therapy (PDT) for cancer treatment; it manufactures and distributes nutraceutical products, naturopathic and homeopathic remedies via Prema Life Pty Ltd, remedial massage and myotherapy services through No More Knots clinics, personalized wellness testing with SkinDNA technology for tailored skin and health products using deoxyribonucleic acid analysis, compounding pharmacy services from Tugun Compounding Pharmacy Pty Ltd, and digital learning platforms from Rayont Technologies; operations span the United States, Australia, New Zealand, China, Malaysia, Sub-Saharan Africa, and internationally with 58 employees generating revenues from nutritional supplements, myotherapy, software, and content. Founded in 2011 and headquartered at 228 Hamilton Avenue, 3rd Floor, Palo Alto, California, United States, the Nevada-incorporated firm holds exclusive licenses for Photosoft technology—an advanced PDT using non-toxic photosensitizers, visible light, and oxygen to produce cytotoxic reactive oxygen that targets malignant cells, shuts down tumors, and stimulates immune response—initially licensed in Australia, New Zealand, China, Malaysia, and Sub-Saharan Africa, with human clinical trials ongoing in Australia and China via Hudson Medical Institute; Rayont International (Labuan) Inc supports commercialization in low-tax jurisdictions. Recent developments include the 2022 acquisition of The SkinDNA Company for AUD 750,000 (approximately USD 500,000) plus shares to bolster personalized wellness leadership, purchase of No More Knots Group companies (No More Knots Pty Ltd, Taringa, Newmarket) for AUD 3.0 million (USD 2.2 million) to expand massage and myotherapy as Australia's largest provider, integration of Tugun Compounding Pharmacy and Ipswich Massage Pty Ltd contributing to revenue growth in nutritional supplements and services, sale of NGPDT license and equipment for Sub-Saharan Africa to Nova Medical Group Pty Ltd in 2022, and plans for Health Script telehealth platform targeting naturopaths in Australia and the USA alongside operational consolidation of Prema Life for cost efficiencies and further healthcare asset acquisitions to drive synergies and profitability.
Beware These 7 Penny Stock Bubbles Getting Ready to Burst
Rayont Inc- RAYT- Reports 10-K/T for the Nine-Month Ending June 30, 2021, Financial Results.
Rayont Inc- RAYT- Reports Six-Month Ending March 31, 2021, Financial Results.
Rayont Names Aleem Sheikh As CEO
Rayont Inc appoints Mr. Aleem Sheikh as President and CEO to position the Company for Growth.